DCGI approves emergency use of Covishield vaccine, know when the vaccination will begin

Share this News:

Shikha Chaurasia

Pune, January 2, 2021: At the beginning of the New Year, the people are going to get the Coronavirus vaccine soon. The Drugs Controller General of India (DCGI) has approved the emergency use of the vaccine. The news agency Reuters has given this information citing a minister of the central government, although an official announcement is yet to be made. Regarding this, the meeting of Drugs Controller General of India continues.

After DCGI approval, vaccination will begin in India on a large scale. On Friday, the Subject Expert Committee (SEC) of DCGI recommended the emergency use of the Coronavirus Vaccine Covishield of the Serum Institute of India (SII).

The Serum Institute of India has partnered with Oxford-AstraZeneca for the Covishield vaccine. On December 30, the UK granted the Oxford University vaccine for emergency use. In India, the procedure for vaccination can be started anytime next week after DCGI gives permission for emergency use of Covishield.
At the same time, dry runs are being rehearsed throughout the country today. Vaccination rehearsals have been successfully completed in Punjab, Gujarat, Assam and Andhra Pradesh on December 28 and 29. 96,000 personnel have been trained all over the country for the vaccination campaign and 83 crore syringes will be needed to administer the vaccine.

Apart from the Serum Institute, Bharat BioNtech and Pfizer have also applied for the emergency use of their vaccines. India is conducting an SEC analysis of the data in addition to Biotech’s COVAXIN and it is believed that it may be recommended to allow its emergency use at any time.

On the other hand, WHO has approved the emergency use of Pfizer-BioNtech vaccine to protect people against COVID-19 and now these vaccines will be made available to poor countries. Until now these vaccines were available only in Europe and North America. Significantly, many countries including the US, UK and European Union have approved this vaccine. This vaccine has to be kept at a very low temperature, which is a major challenge for developing countries.